A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2023-02-21
Adverse events
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-14 (study day 14); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-04-20 (study day 51); relationship: N
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-04-28 (study day 59); relationship: not assessed
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-05-03 (study day 64); relationship: not assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-05-05 (study day 66); relationship: N
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-05-21 (study day 82); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-06-11 (study day 103); relationship: not assessed
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-09-07 (study day 191); relationship: not assessed
Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-09-09 (study day 193); relationship: not assessed
Data queries
No data queries.